9-position Substituted Patents (Class 514/180)
  • Publication number: 20130157963
    Abstract: Compositions and methods related to ophthalmic use of polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.
    Type: Application
    Filed: December 14, 2012
    Publication date: June 20, 2013
    Applicant: ALLERGAN, INC.
    Inventor: ALLERGAN, INC.
  • Publication number: 20130150311
    Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers, and which possesses a Carr index of less than about 20. In other aspects, the present invention is directed a pharmaceutical composition comprising such adjuvant and a pharmaceutically active ingredient; as well as to a method of making the compositions.
    Type: Application
    Filed: December 13, 2011
    Publication date: June 13, 2013
    Inventors: Grzegorz Pietrzynski, Valery Alakhov, Kishore Patel
  • Publication number: 20130142880
    Abstract: The present invention refers to pharmaceutical beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and to their oral use in the treatment of inflammatory pathologies of the intestinal tract. Said compositions in microspheres comprise: a) a core consisting of a microsphere of inert material; b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient; c) a second modified-release gastro-resistant coating. The present invention also refers to a process for obtaining said compositions.
    Type: Application
    Filed: August 2, 2011
    Publication date: June 6, 2013
    Applicant: SOFAR SPA
    Inventor: Carla Labruzzo
  • Publication number: 20130142858
    Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.
    Type: Application
    Filed: May 17, 2011
    Publication date: June 6, 2013
    Applicant: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Chris Sutay
  • Publication number: 20130137668
    Abstract: The invention relates generally to antimicrobial cationic steroid pharmaceutical compositions, methods of making antimicrobial cationic steroid pharmaceutical compositions, and methods of using antimicrobial cationic steroid pharmaceutical compositions.
    Type: Application
    Filed: March 4, 2011
    Publication date: May 30, 2013
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David E. Fein, Robert Bucki, Paul A. Janmey, Scott L. Diamond
  • Publication number: 20130129814
    Abstract: The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 23, 2013
    Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.
    Inventor: ABBOTT CARDIOVASCULAR SYSTEMS INC.
  • Publication number: 20130131024
    Abstract: The present invention provides methods and compositions for the treatment of fluid accumulation in and/or under the retina.
    Type: Application
    Filed: May 10, 2011
    Publication date: May 23, 2013
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Francine Behar-Cohen, Nicolette Farman, Frederic Jaisser
  • Patent number: 8445470
    Abstract: Compositions containing ?2 adrenergic agonists in combination with carbonates and carbamates of the formula. and in combination with related steroid carbonates and carbamates are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilation and for treating rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) and inflammatory diseases, particularly by inhalation.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: May 21, 2013
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Mark G. Currie, Steve Jones, Paul Grover, Chris H. Senanayake, Q. Kevin Fang
  • Patent number: 8445471
    Abstract: A process for obtaining 21-disodium phosphate pregnane derivative compounds of formula (I), wherein X?R?H or X?F and R=?-CH3 or X?F and R=?-CH3: comprises spray drying a solution comprising compound of formula (I).
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: May 21, 2013
    Assignee: Hovione Inter Limited
    Inventors: Luis Sobral, Filipe Gaspar, William Heggie, Emilia Leitao, Jose Rafael Antunes
  • Publication number: 20130116223
    Abstract: Methods relating to local injections of corticosteroids are provided. More specifically intralesional injections of corticosteroids and preferably Triamcinolone and its derivatives are suitable to produce medicaments to be injected in the subcutaneous fat at deep levels to provoke cosmetic lipoatrophy of small fat deposits on the face and body.
    Type: Application
    Filed: March 2, 2010
    Publication date: May 9, 2013
    Inventor: Doris Hexsel
  • Publication number: 20130115293
    Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 50 weight percent of a corticosteroid; and about 50 to about 99 weight percent biocompatible polymer.
    Type: Application
    Filed: June 14, 2012
    Publication date: May 9, 2013
    Inventors: Abhimanyu Sabnis, Greg Troiano
  • Publication number: 20130104881
    Abstract: Pharmaceutical pressurized metered dose inhalers are disclosed having improved temperature and moisture stability comprising CFC-free, ethanol-free compositions that include lactose of particle diameter larger than 1 ?m as a means of minimizing sticking to the walls and other destabilization mechanisms activated by moisture ingress from the environment.
    Type: Application
    Filed: October 31, 2011
    Publication date: May 2, 2013
    Applicant: Laboratorio Pablo Cassara S.R.L.
    Inventors: Fernando Toneguzzo, Julio Cesar Vega
  • Publication number: 20130102579
    Abstract: Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.
    Type: Application
    Filed: December 17, 2012
    Publication date: April 25, 2013
    Applicant: UMECRINE AB
    Inventor: UMECRINE AB
  • Publication number: 20130096097
    Abstract: [Problem] The purpose of the present invention is to provide organic particles containing pharmaceutical particles of which the particles are small and the particle size distribution is narrow, and a manufacturing method for the same. [Solution] Provided are pharmaceutical multimeric particles of which the particles are small and the particle size distribution is narrow and which are characterized in being obtained by pouring into water a solution of a pharmaceutical multimer dissolved in a water-miscible organic solvent, and a manufacturing method for the pharmaceutical multimeric particles. Pharmaceutical dimeric particles thereof are characterized in being obtained by pouring into water a solution of a compound represented by general formula (I) dissolved in a water-miscible organic solvent.
    Type: Application
    Filed: June 7, 2011
    Publication date: April 18, 2013
    Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Hitoshi Kasai, Hachiro Nakanishi, Koichi Baba, Hidetoshi Oikawa, Tastuya Murakami, Hiroshi Imahori, Misturu Hashida, Isamu Oh
  • Publication number: 20130071321
    Abstract: The invention described herein pertains to folate-receptor targeted agents comprising therapeutic agents useful for the treatment of inflammatory disease, including folate-receptor targeted liposomes (folate-targeted liposomes) containing entrapped therapeutic agents and folate-receptor targeted dendrimers conjugated to therapeutic agents (folate-targeted dendrimer conjugates), useful for the treatment of inflammatory disease, including auto-immune disease, as well as to folate-targeted liposomes containing entrapped imaging agents and dendrimer conjugates conjugated to imaging agents, for use in the diagnosis and monitoring of treatment in such disease.
    Type: Application
    Filed: May 27, 2011
    Publication date: March 21, 2013
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventors: Philip Stewart Low, Scott Poh
  • Publication number: 20130065842
    Abstract: Heterocyclic compounds, and pharmaceutical compositions thereof, are disclosed as ROR?t modulators that have a formula represented by the following: and wherein n1, n2, R1, R2, R3, and R4 are as described herein. These compounds may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.
    Type: Application
    Filed: March 11, 2011
    Publication date: March 14, 2013
    Inventors: Dan Littman, Jun R. Huh, Wenwei Huang, Ruili Huang
  • Publication number: 20130028955
    Abstract: A solid dosage form suitable for forming a tablet for the containment and delivery of medicament is provided wherein the matrix forming material is a pressure sensitive adhesive, present in the amount from about 0.1 to about 40 weight %, based on the total weight of the composition. The dosage form is comprised of the medicament and a water-insoluble polymer silicone pressure sensitive adhesive and allows release of the medicament in a controlled fashion depending on simple parameters such as weight percent of the polymer silicone adhesive. A sustained release dosage form is provided for delivery of medicament wherein the release rate of medicament does not depend on the dissolution medium of the pH. Another aspect of invention is formation of solid tablets of poorly compressible material and the method for making the solid composition. The dosage form for this invention s particularly suitable for oral dosage forms.
    Type: Application
    Filed: July 25, 2011
    Publication date: January 31, 2013
    Inventor: Gaurav Thakersi Tolia
  • Publication number: 20130023509
    Abstract: Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.
    Type: Application
    Filed: September 28, 2012
    Publication date: January 24, 2013
    Applicant: ADVANCED CARDIOVASCULAR SYSTEMS, INC.
    Inventor: ADAVANCED CARDIOVASCULAR SYSTEMS,IN
  • Publication number: 20130023507
    Abstract: Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.
    Type: Application
    Filed: September 28, 2012
    Publication date: January 24, 2013
    Applicant: ADVANCED CARDIOVASCULAR SYSTEMS, INC.
    Inventor: ADVANCED CARDIOVASCULAR SYSTEM, INC.
  • Publication number: 20130023508
    Abstract: Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.
    Type: Application
    Filed: September 28, 2012
    Publication date: January 24, 2013
    Applicant: ADVANCED CARDIOVASCULAR SYSTEMS, INC.
    Inventor: ADVANCED CARDIOVASCULAR SYSTEMS, IN
  • Publication number: 20130018299
    Abstract: Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.
    Type: Application
    Filed: September 20, 2012
    Publication date: January 17, 2013
    Applicant: Advanced Cardiovascular Systems, Inc.
    Inventor: Adanced Cardiovascular Systems, Inc.
  • Patent number: 8349295
    Abstract: A method and apparatus for multicomponent surface modified aerosol particle production suitable for, for instance, therapeutic, cosmetic or diagnostic use in which an aerosol containing an active agent is introduced in an aerosol reactor together with a surface agent or surface agent source and/or precursor and wherein the surface agent and/or surface agent precursor is volatilizable. The surface agent vapor saturation ratio is elevated so to cause it to nucleate from the gas phase. Reactor conditions are maintaining such that the active agent remains in the condensed phase and provides a surface for the surface agent to deposit on the active agent containing aerosol particle thus producing surface modified aerosol particles. The method can be used for batch or continuous production. Particles made according to the method and powders and dispersions containing the particles are also described.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: January 8, 2013
    Assignee: Teicos Pharma Oy
    Inventors: David P. Brown, Esko I. Kauppinen, Anna Lahde, Janne Raula
  • Publication number: 20120328531
    Abstract: The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C2-C4 alcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C2-C4 alcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9?-fluoro-11?-hydroxy-16?-methyl-androsta-1,4-diene-3-one under an accelerated storage condition.
    Type: Application
    Filed: September 6, 2012
    Publication date: December 27, 2012
    Applicant: Taro Pharmaceuticals North America, Inc.
    Inventors: Srinivasa Rao, Suresh Dixit, Avraham Yacobi, Arthur Bailey
  • Patent number: 8337873
    Abstract: This invention relates to the synthesis of new tooth or bone from an encapsulated biological agent such as a growth factor or stem cells contained within a hollow and porous biocompatible vehicle such as a titanium implant placed (implanted) within the body of a host animal such as a human.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: December 25, 2012
    Assignee: The Board of Trustees of the University of Illinois
    Inventor: Jeremy Jian Mao
  • Publication number: 20120321673
    Abstract: A transdermal drug delivery system comprising a steroid as an active agent, wherein the steroid may be clobetasol propionate, betamethasone dipropionate, amcinonide, or loteprednol etabonate. The transdermal drug delivery system also comprises a pressure-sensitive adhesive layer and a support, wherein the steroid is present in the pressure-sensitive adhesive layer, and wherein the pressure-sensitive adhesive layer is provided on a support. The transdermal drug delivery system may be applied onto the eyelid of a patient in need thereof, in order to treat a disease of the eyelid, such as chalazion, blepharitis or meibomian gland dysfunction.
    Type: Application
    Filed: June 20, 2011
    Publication date: December 20, 2012
    Inventors: Takahiro OGAWA, Akiharu Isowaki
  • Publication number: 20120315324
    Abstract: An exosomal composition is provided that comprises a therapeutic agent encapsulated by an exosome. The therapeutic agent can be a phytochemical agent, a chemotherapeutic agent, or a Stat3 inhibitor. Pharmaceutical compositions comprising the exosomal compositions are also provided. Methods for treating an inflammatory disease or a cancer are further provided and include administering an effective amount of an exosomal composition to a subject in need thereof to thereby treat the inflammatory disorder or the cancer.
    Type: Application
    Filed: February 4, 2011
    Publication date: December 13, 2012
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventor: Huang-Ge Zhang
  • Publication number: 20120309722
    Abstract: The invention features pharmaceutical compositions and dosing regimens for the treatment of immunoinflammatory disorders.
    Type: Application
    Filed: August 16, 2012
    Publication date: December 6, 2012
    Inventor: Mahesh Padval
  • Patent number: 8324192
    Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: December 4, 2012
    Assignee: The Regents of the University of California
    Inventors: Ranjan Dohil, John Bastian, Seema S. Aceves
  • Publication number: 20120301511
    Abstract: Formulation in the form of aqueous suspension of drug particles of a corticosteroid for topical administration are effective for the prophylaxis and/or treatment of a dermatological disease such as atopic dermatitis, acne and psoriasis.
    Type: Application
    Filed: May 2, 2012
    Publication date: November 29, 2012
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventor: Salvatore Criscione
  • Publication number: 20120302534
    Abstract: The present invention relates to a compound characterized by the following Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X, and Y are as described herein. Compounds of the present invention are useful for the treatment of HIV-1.
    Type: Application
    Filed: February 9, 2011
    Publication date: November 29, 2012
    Inventors: Daxin Gao, Nianhe Han, Zhimin Jin, Fangxian Ning, Jun Tang, Yongyong Wu, Heping Yang
  • Publication number: 20120294907
    Abstract: The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and at least two solidifying agents. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent, wherein at least one non-volatile solvent is flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.
    Type: Application
    Filed: August 6, 2012
    Publication date: November 22, 2012
    Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
  • Publication number: 20120294945
    Abstract: The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect.
    Type: Application
    Filed: December 15, 2011
    Publication date: November 22, 2012
    Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Sei Kwang HAHN, Choun-Ki Joo, Yoon Keun Kim, Seung Kew Yoon, Eun Ju Oh, Ki Su Kim, Hyemin Kim, Kitae Park, Jeong-A Yang, Jun-sub Choi, You Me Tae, Wonhee Hur
  • Publication number: 20120294926
    Abstract: The present invention is drawn to adhesive formulations and methods of drug delivery. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least two volatile solvents, and a non-volatile solvent system including at least one non-volatile solvent, wherein at least one non-volatile solvent is capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.
    Type: Application
    Filed: August 3, 2012
    Publication date: November 22, 2012
    Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
  • Publication number: 20120283233
    Abstract: The present invention relates to a carrier composition comprising a phosphate compound of an electron transfer agent and a polar aprotic solvent. Biologically active compounds formulated with the carrier composition have been shown to have improved properties.
    Type: Application
    Filed: February 4, 2011
    Publication date: November 8, 2012
    Inventors: Paul David Gavin, Mahmoud El-Tamimy, Roksan Libinaki, Mohammad Reza Mozafari
  • Publication number: 20120283232
    Abstract: Process for making a sterile, injectable pharmaceutical composition by combining triamcinolone, a buffer and a high viscosity hyaluronate.
    Type: Application
    Filed: December 7, 2007
    Publication date: November 8, 2012
    Inventors: Zhengjun Wang, Thomas M. McGrath, Toan N. Ha, Sam W. Lam, Bruce A. Firestone, Robert T. Lyons, James N. Chang, John T. Trogden
  • Publication number: 20120283217
    Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.
    Type: Application
    Filed: July 16, 2012
    Publication date: November 8, 2012
    Applicant: SATORI PHARMACEUTICALS, INC.
    Inventors: Mark A. Findeis, Steffen P. Creaser
  • Publication number: 20120277178
    Abstract: Compositions and methods of treatment or prophylaxis of fragile-X associated disorders are provided, as well as methods of screening compounds and kits to screen a library of compounds.
    Type: Application
    Filed: April 27, 2012
    Publication date: November 1, 2012
    Applicant: EMORY UNIVERSITY
    Inventors: Peng JIN, Abrar QURASHI
  • Publication number: 20120263779
    Abstract: A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics.
    Type: Application
    Filed: June 13, 2012
    Publication date: October 18, 2012
    Inventors: Robert T. Lyons, James A. Burke, Michael R. Robinson
  • Patent number: 8288445
    Abstract: Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: October 16, 2012
    Assignee: Nycomed GmbH
    Inventor: Ruth Wayland
  • Publication number: 20120238536
    Abstract: Composition comprising at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, said composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably comprised between 0.90 and 1, or a density above 1 more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of said composition.
    Type: Application
    Filed: November 19, 2010
    Publication date: September 20, 2012
    Applicant: NOVAGALI PHARMA SA
    Inventors: Jean-Sebastien Garrigue, Frederic Lallemand, Jeffrey Heier
  • Publication number: 20120238535
    Abstract: A new topical formulation is provided, with a high chemical stability, of for example a low dose clobetasol propionate, suitable for the topical treatment of skin and mucous membrane conditions associated with disorders including psoriasis, eczema, and other forms of dermatitis and also topical use associated with he mouth, such as lichen planus. The formulation includes an aqueous vehicle of based on propylene glycol as a solvent and moisture-retaining agent, and macrogol-glycerol hydroxystearate as a non-ionic emulsifier, being capable of holding surprisingly low concentrations of clobetasol. The vehicle holds concentrations about 0.005% to about 0.05% by weight of 17-clobetasol propionate, more preferably about 0.02 to 0.025%, even more preferably 0.025% by weight of 17-clobetasol propionate. The formulation has a good chemical stability, resulting in a long durability.
    Type: Application
    Filed: May 1, 2012
    Publication date: September 20, 2012
    Inventor: Jan G. Smith
  • Publication number: 20120231061
    Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.
    Type: Application
    Filed: March 9, 2012
    Publication date: September 13, 2012
    Inventors: Petr KUZMA, Harry QUANDT
  • Publication number: 20120231072
    Abstract: A thermo-responsive hydrogel, including a biocompatible monomer and/or polymer having an amino acid side chain. The hydrogel is thermo-responsive at a physiological temperature, and can include, incorporate, or encapsulate a treatment agent, such as a drug composition, a biomolecule, and/or a nanoparticle. The hydrogel is useful in delivering the treatment agent. The hydrogel is in a first physicochemical state for administration to a mammal. The hydrogel is thermo-responsive at a physiological temperature of the mammal, and changes to a second physicochemical state that is more solid than the first physicochemical state. In the second physicochemical state the thermo-responsive hydrogel releases the treatment agent.
    Type: Application
    Filed: March 11, 2011
    Publication date: September 13, 2012
    Applicants: Chemisches Institut Schaefer AG, Illinois Institute of Technology
    Inventors: Jennifer J. KANG-MIELER, Eric BREY, Victor PEREZ-LUNA, Bin JIANG, Pawel DRAPALA, Hans Hitz, Rolf Schaefer
  • Publication number: 20120219599
    Abstract: The present disclosure describes an implant for improving bone growth including an osteoconductive scaffold and an osteoinductive small molecule. The osteoconductive scaffold can further include a polymeric binder. The implant can also include an osteogenic material to provide a viable cell population to assist the bone repair and remodeling. Also disclosed is a system for forming an implant for improving bone growth, as well as methods for forming the implant according to the disclosure, in addition to methods of therapeutic use of the implant.
    Type: Application
    Filed: February 24, 2012
    Publication date: August 30, 2012
    Inventors: Meredith Hans Moore, Doug Buechter, Melissa Brown, Lisa Hughes, Stephen Hornsby
  • Patent number: 8242099
    Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 ?g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 ?g/ml dexamethasone for at least about three weeks.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: August 14, 2012
    Assignee: Allergan, Inc.
    Inventors: Vernon G. Wong, Mae W. L. Hu
  • Publication number: 20120201800
    Abstract: The present invention includes methods and devices for providing sustained in-vivo release of an active agent to a subject. In some aspects, such release may be achieved by reacting an active agent in-vivo with a depot forming agent in order to form a sustained release active agent depot inside the subject. The depot can then release the active agent over a sustained period of time.
    Type: Application
    Filed: August 8, 2011
    Publication date: August 9, 2012
    Inventors: John W. Higuchi, S. Kevin Li, William I. Higuchi, Matthew S. Hastings
  • Publication number: 20120201862
    Abstract: The present invention relates to a process for the preparation of colloidal systems, such as nanocapsules and nanoparticles, which incorporates a homogenization step for reducing particle size.
    Type: Application
    Filed: June 7, 2010
    Publication date: August 9, 2012
    Inventors: Ana Belén Cuesta Regueiro, Ana Isabel Vila Pena
  • Publication number: 20120202780
    Abstract: A carrier composition of the present invention comprises a phosphate compound of an electron transfer agent and a relatively high concentration of a polar protic solvent. A biologically active compound may be formulated with a carrier composition of the present invention to provide a formulation.
    Type: Application
    Filed: December 22, 2010
    Publication date: August 9, 2012
    Inventors: Paul David Gavin, Mahmoud El-Tamimy, Jeremy James Cottrell, Giacinto Gaetano, Nicholas John Kennedy
  • Publication number: 20120195932
    Abstract: The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed about a hydrophobic domain is also disclosed. The vehicle can be incorporated into a variety of medicinal, food preparations, and personal care products to deliver or stabilize a cargo moiety. Packaged delivery vehicles for to later addition of cargo moieties are also contemplated.
    Type: Application
    Filed: January 25, 2010
    Publication date: August 2, 2012
    Applicant: BioDelivery Sciences International, Inc.
    Inventors: Raphael J. Mannino, Sara L. Krause-Elsmore, Susan Gould-Fogerite, David Delmarre, Ruying Lu
  • Patent number: 8232264
    Abstract: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: July 31, 2012
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Eugene H. Gans, Mitchell S. Wortzman